ASTRAVA BIOSCIENCES
Helping medicines cross species and environments,
from Earth to Mars.
Space is no longer only a destination. It is becoming a new biological test environment, and Astrava is building the decision layer that lets medicines learn across species, gravity and stress.
Why Now
Three curves are converging into a new pharmaceutical environment.
Space pharmacology is becoming practical because orbital access, flight-ready biology and AI modeling are moving at the same time. Astrava turns that convergence into a staged R&D system: Earth value first, space-differentiated validation next.
Astrava wedge
The near-term product is not a Mars pharmacy. It is a translational decision system that uses extreme environments to reveal which mechanisms remain robust.
Access
LEO is becoming infrastructure
Commercial launch cadence and post-ISS station plans are turning low Earth orbit from rare mission capacity into a repeatable research interface.
Biology
Assays can now fly small
Organ-on-chip, microfluidics and miniaturized readouts make meaningful biology possible without waiting for full-scale orbital manufacturing.
Modeling
AI can learn from sparse perturbations
Small-N cross-environment data becomes useful when it is connected to mechanism, species evidence, PK/PD, toxicity and ground-control context.
The Insight
Medicines should not be designed for a single species or a single environment.
Animal efficacy does not equal human efficacy; Earth efficacy does not guarantee extreme-environment robustness. Astrava looks for translational invariants that survive both axes.
Boundary 01
From animals to humans
Quantify how activity, exposure, toxicity and biomarker signals migrate across human, dog, mouse and NHP for the same target and molecule.
Boundary 02
From Earth to perturbation
Treat gravity, radiation and long-term storage as experimental variables; use microgravity as an accelerated-aging perturbation for mechanism robustness testing.
ASTRA-Tx Engine
The model is only a node. The loop is the product.
ASTRA-Tx is built around a data axis ground-only platforms cannot fully reconstruct: how the same mechanism behaves across species, gravity states, radiation stress and assay context. Each study updates the evidence state, and each update makes the next experiment sharper.
Environment data becomes a compounding translational asset, not a one-off space experiment.
The product is a decision layer: what to test next, what risk moved, and what evidence survives across axes.
Space Pharmacology
Space Pharmacology turns gravity into a controllable translational variable.
This Space Pharmacology research frames the field as the systematic study of how gravity, simulated microgravity, orbital microgravity and radiation affect both drug substances and biological systems, then proposes translational invariance as a standard for cross-species and cross-environment decisions.
It explains why the environment axis is not decoration, but an orthogonal perturbation that ground-only models cannot replicate.
It connects microgravity biology in cytoskeleton, proteostasis, innate immunity and DNA damage to cGAS / HDAC6 program logic.
It proposes a ground to simulated microgravity to orbital calibration funnel, plus Perturbation-Invariance and Space-Readiness scoring.
Research Flow
From computational prioritization to environment-aware translational insight.
ASTRA-Tx connects computational models, multi-species experiments and microgravity research into a continuous workflow where each evidence layer informs the next R&D decision.
Pipeline
Building an Earth-to-deep-space pipeline around key mechanisms of space-accelerated aging.
Astrava focuses on DNA damage, inflammaging, and proteostasis, using microgravity and radiation as accelerated perturbation variables to identify drug intervention mechanisms that remain valid across species and environments.
cGAS · DNA damage / cellular senescence / innate immunity
The lead research program. It studies cytosolic DNA sensing, cGAS-STING activation, and type I interferon responses triggered by space radiation and cellular stress, and their roles in cellular senescence, inflammaging, and immune-related disease.
The near-term focus is cGAS small-molecule series optimization, mechanistic studies, and biomarker translation across human, mouse, and dog models.
Space relevance
Space radiation · DNA damage · immune dysregulation
Earth relevance
Autoimmunity · chronic inflammation · cellular senescence
NLRP3 · inflammaging / vascular aging / metabolic inflammation
A discovery-stage program studying how microgravity, oxidative stress, and cellular injury activate the NLRP3 inflammasome and drive endothelial dysfunction, chronic low-grade inflammation, and age-related tissue damage.
The program will use IL-1β, IL-18, caspase-1, and pyroptosis readouts to build inflammatory response matrices across ground gravity, simulated microgravity, and multi-species conditions.
Space relevance
Microgravity · endothelial injury · immune inflammation
Earth relevance
Inflammaging · cardiovascular aging · neuro-metabolic inflammation
HDAC6 · cytoskeleton / proteostasis / neuro-aging
An exploratory program around HDAC6 regulation of alpha-tubulin acetylation, microtubule transport, autophagy, and abnormal protein clearance, studying how cells maintain structure and proteostasis under microgravity and other environmental stresses.
The program combines the team’s existing HDAC6 small-molecule research base with translational exploration in neurodegenerative disease, muscle functional decline, and cross-species homologous disease.
Space relevance
Cytoskeletal perturbation · autophagy imbalance · neuromuscular stress
Earth relevance
Proteostasis loss · neurodegenerative disease · healthy aging
Development Roadmap
Turning cross-species and cross-environment capabilities into long-term platform assets.
The path is staged deliberately: prove translation value on Earth, then use simulated and orbital environments as a second validation axis.
Advance molecular prioritization and mechanistic validation across cGAS, NLRP3, and HDAC6 programs, building an internal research matrix across DNA damage, inflammatory response, and proteostasis.
Build biomarker comparison systems across human-derived cells, mouse models, and canine disease data to identify pharmacological responses that remain consistent across species.
Compare target pathways, efficacy, and toxicity under normal gravity, simulated microgravity, and radiation conditions to generate an Environment Robustness Score.
Prioritize programs that can produce clear readouts in miniaturized cell or organoid systems, establishing scientific design and ground-control foundations for future orbital experiments.
Partnership Focus
Connecting drug discovery, translational science and space pharmacology collaboration.
Therapeutic Programs
Use internal programs such as AST-101 to build target, biomarker and small-molecule optimization experience in real disease contexts.
Translational Science
Organize multi-species data, computational models, PK / PD, toxicology and biomarker evidence into an auditable R&D decision framework.
Space Pharmacology
Collaborate with research institutions, pharma companies and space-experiment partners to study drug robustness under microgravity and radiation.
Team
A cross-disciplinary team for space pharmacology.
The team goes beyond AI and pharmaceutical R&D by connecting candidate molecules, biomarkers, microgravity readouts and ground-control design, moving programs from terrestrial validation toward orbital experiment readiness.
Ground-to-Orbit Team
From ground models to orbital payloads, making space pharma an executable R&D system.
Astrava translates AI screening, small-molecule optimization, cGAS / NLRP3 / HDAC6 mechanism research and multi-species validation into comparable readouts under microgravity, radiation and long-duration flight conditions.
Keda Che
Founder & CEO / Frontier Technology Commercialization
Category creation and platform strategy
Prof. Haoliang Yuan
AI Drug Screening Expert / Space Pharmacology Research
Microgravity efficacy readouts
Prof. Xin Chen
Small-Molecule Drug R&D / HDAC6 Research Expert
Space-accelerated aging biology
Dr. Lei Ding
AI architecture & species modeling
Orbital data/model loopContact
Turn cross-species and cross-environment evidence into the next R&D decision.
For translational pharmacology partnerships, microgravity study design, payload resources, or seed-stage investor inquiries, contact us by email.